Eugene P.. Kennedy, MD
Philadelphia, PA 19107
Most Recent Peer-reviewed Publications
- Hitler's gift and the era of biosynthesis.
- Domains of Escherichia coli acyl carrier protein important for membrane- derived-oligosaccharide biosynthesis
- UTP:α-D-glucose-1-phosphate uridylyltransferase of Escherichia coli: Isolation and DNA sequence of the galU gene and purification of the enzyme
- Sailing to Byzantium
- Membrane-derived oligosaccharides affect porin osmoregulation only in media of low ionic strength
MD, University of Virginia - 1996
Assistant Professor, Surgery
Thomas Jefferson University
Research and Clinical Interests
My interest in therapeutic vaccines for cancer dates to my surgical residency and post-graduate training when I spent three years in the laboratory of Dr. Drew Pardoll at Johns Hopkins. There I worked on several novel approaches to improving the efficacy of GM-CSF based cellular vaccines through augmented costimulation.
Currently, I focus on the treatment of patients with pancreatic cancer. In additional to my clinical practice, I have ongoing projects in both clinical and translational research. I am currently in the process of submitting to the IRB a clinical trial for a phase II cell based pancreatic cancer vaccine. In the lab, I am collaborating with Drs. Brody and Witkiewicz on several projects. We are evaluating the role of Indoleamine 2,3-Dioxygenase (IDO) in pancreatic cancer. The goal of this project is to assess the potential of IDO inhibition as an adjuvant to conventional or vaccine based cancer therapy. Additionally, we are also looking at the humoral response of patients to pancreatic cancer, identifying and developing human antibodies against Prostate Stem Cell Antigen (PSCA) for diagnostic and therapeutic purposes.